Gene defect biomarker for targeted prostate cancer therapy
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The loss of CHD1, one of the most mutated genes in prostate tumours, sensitises human prostate cancer cells to different drugs, a biomarker for...